Posted by Michael Wonder on 10 May 2022
Exit Aduhelm, enter lecanemab. Biogen and Eisai have another go
10 May 2022 - Here we go again. With Aduhelm largely sidelined, Biogen and Eisai are hoping for a better fortunes with their next Alzheimer’s disease therapy lecanemab, which is now fully filed with the FDA.
The two partners have also requested a priority review for the biologics license application for lecanemab, which if granted by the FDA could result in an approval before the end of the year.
